lysyl oxidase Inhibitors
2 drugsAbout lysyl oxidase
Lysyl oxidase (LOX) is an enzyme essential for crosslinking collagen and elastin in the extracellular matrix, providing structural integrity to tissues.
LOX's role in matrix remodeling makes it a potential drug target, though no genetic evidence currently links it to specific diseases.
Two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, target LOX, both marketed by AM REGENT for other therapeutic areas.
Top lysyl oxidase Drugs
AM REGENT is the only company with approved drugs targeting lysyl oxidase.
Low competition suggests an opportunity for new entrants in the lysyl oxidase space.
lysyl oxidase Drug Modality Landscape
Modalities
Routes of Administration
lysyl oxidase is druggable by small molecules, though no oral formulations are currently approved.
The modality landscape suggests an opportunity to explore alternative modalities like antibodies.
lysyl oxidase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on lysyl oxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
lysyl oxidase Drug Approval Timeline (2020 - 2020)
The first and most recent drug approvals for lysyl oxidase were in 2020.
Recent approvals indicate renewed interest, but saturation may occur without new innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on lysyl oxidase. A trial counts if an approved drug acting on lysyl oxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.